Navigation Links
TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F-expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved specific therapies for PV, ET and PMF. These disorders are estimated to affect approximately 200,000 patients in the United States and more than twice that total worldwide.

The current clinical trial is being conducted at multiple centers in the USA. The trial is expected to enroll between 40-80 patients. Primary goals of this open label dose escalating protocol include identification of a maximum tolerated dose (MTD), accumulation of safety data, measurement of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis ... global Hemophilia market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... 24, 2017 , ... With millions of Americans and people ... we all are aware of our options and are empowered with strength and ... launch of its newest edition of "Vision and Hearing" in USA Today, that ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ... have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual ... X. , With ProGlass Prism users are given the tools and effects to ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
Breaking Medicine News(10 mins):